How it works
From press release to
answer you can defend.
Somebody publishes a financing, a trial update or a licensing deal. Not long after, it is part of your map, filed by the science and carrying the document it came from. Here is what happens in between, and what each part of it means for the answers you get back.
In: a press release
- 01
Watched
Trade press, registries, filings and company announcements.
- 02
Filed
By indication, mechanism, phase and partner.
- 03
Reconciled
Three spellings of one investor become one record.
- 04
Sourced
The document and the sentence stay attached.
Out: a fact you can defend
+ its sourceIt reads what your analyst would have read
The trade press, ClinicalTrials.gov, regulatory filings and company announcements, watched continuously rather than checked when somebody remembers. A financing, readout or licensing deal published this morning is on the map today, not in a queue for the next refresh.
Everything is filed by the science
Each new item is sorted into what it actually is: which company, which program, which indication, which mechanism, which phase, which partner. That filing is why you can ask for Phase 2 assets in your indication with no large-pharma partner and get a list, rather than a keyword search and a week of reading.
One company, not four spellings
“Arch”, “ARCH Venture” and “Arch Venture Partners” are one investor, and the map treats them as one, so a count is a count and a syndicate is complete. Where a match is uncertain, a person checks it before it becomes part of the record, rather than after you have relied on it.
Every fact arrives with its receipt
Alongside each fact is the document it came from and the exact sentence it was taken from. You can follow any claim back to its source in one step, which is what lets you hand the answer to an investment committee without hedging it first.
What you get back
Five things you can do the moment you open it.
- Screen an indication by phase, mechanism, modality and partnership status.
- Pull a cited page on any company: programs, trials, financing history, investors, partners.
- Follow a connection outward, from a company to its trials to the investors behind them.
- Ask a question in plain language and get an answer with its sources shown.
- Watch a company, an investor, a target or a whole indication, and hear about changes as they land.
Relationship
Meridian Cardiolicensed toNorthlake Therapeutics
Verbatim snippet
“Under the agreement, Northlake receives exclusive ex-US rights to the Phase 2 asset, with milestones tied to first regulatory submission.”
- Source
- businesswire.com
- Confidence
- 0.94
- Extracted
- 2026-03-04
- Fingerprint
- claude-opus-5 · a17f39c2b8e1 · run 7c41d9
The standard
Intelligence you can't cite is opinion.
Every fact on the map keeps the document it came from and the sentence it was taken from, and both are attached to the fact rather than to a bibliography somewhere else. That is what lets you put an answer in front of an investment committee or a board without caveats, and it is why we say plainly that if we can't source it, we don't state it. The figures shown across this site are illustrative placeholders, labeled as such; the real map is built only from cited events.
See a sample map and dossier →How Terrane avoids inventing things →
See your corner of the map.
Early access is open for life sciences investors, business development and strategy teams, competitive intelligence groups, and founders.